Medicare Will Require MAC Transparency as NCPA Urged

NCPA has commended Medicare for taking positive steps on generic drug reimbursement procedures by Part D plans, actions NCPA has tirelessly advocated for years. Last Monday CMS said for the 2016 plan year it would require sponsors to both disclose to pharmacies the maximum allowable cost (MAC) reimbursement limits for many generic drugs and to update MAC-based reimbursement every seven days to better reflect market costs.